Stocks
Neurocrine Biosciences, Inc.NBIX
NASDAQHealthcareBiotechnology$129.78+1.57%
Focused on neuroscience, this biopharmaceutical company develops treatments for neurological, endocrine, and psychiatric disorders. Its commercial products include Ingrezza for tardive dyskinesia and Ongentys for Parkinson’s, with a pipeline targeting high-need CNS conditions. Investors monitor its specialty drug commercialization and late-stage clinical trials in niche neurological markets.
Market Cap: $13.0B52W Range: $84.23 – $160.18
Congressional Interest in Neurocrine Biosciences, Inc. (NBIX)
5 members of Congress have disclosed 23 trades in Neurocrine Biosciences, Inc. (NBIX), a Healthcare company. The buy/sell breakdown shows 8 purchases versus 15 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
23
Unique Politicians
5
Buys
8
Sells
15
Who in Congress Is Trading NBIX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-06-17 | Lisa McClain | sell | $1K – $15K |
| 2025-06-11 | Lisa McClain | buy | $1K – $15K |